
James Bentley

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10540104/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Psychosocial Distress in Adult Patients Awaiting Cancer Surgery during the COVID-19 Pandemic. Current Oncology, 2021, 28, 1867-1878.	0.9	26
2	A health economic model to estimate the costs and benefits of an mRNA vs DNA high-risk HPV assay in a hypothetical HPV primary screening algorithm in Ontario, Canada. Preventive Medicine Reports, 2021, 23, 101448.	0.8	5
3	New approaches to cancer care in a COVID-19 world. Lancet Oncology, The, 2020, 21, e339-e340.	5.1	18
4	Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care. International Journal of Gynecological Cancer, 2020, 30, 1748-1756.	1.2	24
5	Justifying conservative management of CIN2 in women younger than 25†years - A population-based study. Gynecologic Oncology, 2019, 152, 82-86.	0.6	15
6	Recurrent Vulvar Cancer on the Ankle. Journal of Obstetrics and Gynaecology Canada, 2019, 41, 141.	0.3	0
7	Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm. Preventive Medicine, 2017, 98, 5-14.	1.6	87
8	Approaches for triaging women who test positive for human papillomavirus in cervical cancer screening. Preventive Medicine, 2017, 98, 15-20.	1.6	34
9	Prise en charge colposcopique des résultats cytologiques et histologiques anormaux en ce qui concerne le col utérin. Journal of Obstetrics and Gynaecology Canada, 2016, 38, S171-S188.	0.3	0
10	Persistent mild increase of human chorionic gonadotropin levels in a 31-year-old woman after spontaneous abortion. Cmaj, 2016, 188, E504-E508.	0.9	3
11	Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. Oncolmmunology, 2015, 4, e1026529.	2.1	79
12	Safety, immunogenicity, and clinical activity of the immunotherapeutic vaccine, DPX-Survivac, in a Phase 1/1b trial of women with ovarian, fallopian tube, or peritoneal cancer Journal of Clinical Oncology, 2015, 33, 3072-3072.	0.8	2
13	Long-term Outcomes and Late Effects of Definitive Chemoradiotherapy in Patients with Cervical Cancer in Nova Scotia. Cureus, 2015, 7, e343.	0.2	2
14	Phase I/Ib clinical and immunologic assessment of immunotherapeutic vaccine, DPX-Survivac in women with ovarian, Fallopian tube, or peritoneal cancer (OC) Journal of Clinical Oncology, 2014, 32, 5555-5555.	0.8	1
15	Performance of proex c and pretect hpvâ€proofer e6/e7 mrna tests in comparison with the hybrid capture 2 hpv dna test for triaging ascus and Isil cytology. Diagnostic Cytopathology, 2013, 41, 767-775.	0.5	24
16	Effect of oral cyclophosphamide on the immunogenicity of DPX-Survivac in ovarian cancer patients: Results of a phase I study Journal of Clinical Oncology, 2013, 31, 3030-3030.	0.8	4
17	2011 Colposcopic Terminology of the International Federation for Cervical Pathology and Colposcopy. Obstetrics and Gynecology, 2012, 120, 166-172.	1.2	306
18	Colposcopic Management of Abnormal Cervical Cytology and Histology. Journal of Obstetrics and Gynaecology Canada, 2012, 34, 1188-1202.	0.3	70

JAMES BENTLEY

#	Article	IF	CITATIONS
19	Aptima HPV E6/E7 mRNA Test Is as Sensitive as Hybrid Capture 2 Assay but More Specific at Detecting Cervical Precancer and Cancer. Journal of Clinical Microbiology, 2011, 49, 557-564.	1.8	114
20	Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada. Journal of Medical Virology, 2011, 83, 1034-1041.	2.5	61
21	Clinical Performance of the PreTect HPV-Proofer E6/E7 mRNA Assay in Comparison with That of the Hybrid Capture 2 Test for Identification of Women at Risk of Cervical Cancer. Journal of Clinical Microbiology, 2010, 48, 2779-2785.	1.8	71